Financial reports
20-F
2023 FY
Annual report (foreign)
28 Sep 23
20-F
2022 FY
Annual report (foreign)
9 Sep 22
20-F
2021 FY
Annual report (foreign)
29 Oct 21
20-F
2020 FY
Annual report (foreign)
28 Oct 20
20-F
2019 FY
Annual report (foreign)
25 Oct 19
20-F
2018 FY
Annual report (foreign)
31 Oct 18
20-F
2017 FY
Annual report (foreign)
2 Nov 17
NT 20-F
Notice of late annual filing (foreign)
31 Oct 17
Current reports
6-K
Report of Foreign Private Issuer
14 Mar 24
6-K
Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
7 Mar 24
6-K
Report of Foreign Private Issuer
4 Mar 24
6-K
Results for announcement to the market
28 Feb 24
6-K
Report of Foreign Private Issuer
21 Feb 24
6-K
Immuron achieves record Travelan® sales
13 Feb 24
6-K
Investor Webinar Presentation
9 Feb 24
6-K
Immuron achieves record half yearly Travelan® sales
16 Jan 24
6-K
Immuron Clinical Trials Update
22 Dec 23
6-K
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study
4 Dec 23
Registration and prospectus
25-NSE
Exchange delisting
10 Jun 22
424B5
Prospectus supplement for primary offering
23 Jul 20
424B5
Prospectus supplement for primary offering
17 Jul 19
424B5
Prospectus supplement for primary offering
16 Jul 19
424B5
Prospectus supplement for primary offering
28 May 19
424B5
Prospectus supplement for primary offering
23 May 19
F-3
Shelf registration (foreign)
8 Apr 19
RW
Registration withdrawal request
8 Apr 19
F-3
Shelf registration (foreign)
1 Apr 19
POS AM
Prospectus update (post-effective amendment)
14 Jan 19
Proxies
No filings
Other
EFFECT
Notice of effectiveness
18 Apr 19
CORRESP
Correspondence with SEC
15 Apr 19
UPLOAD
Letter from SEC
11 Apr 19
EFFECT
Notice of effectiveness
11 Feb 19
UPLOAD
Letter from SEC
11 Jul 17
UPLOAD
Letter from SEC
11 Jul 17
UPLOAD
Letter from SEC
11 Jul 17
CT ORDER
Confidential treatment order
12 Jun 17
EFFECT
Notice of effectiveness
8 Jun 17
CORRESP
Correspondence with SEC
6 Jun 17